Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. The company is headquartered in Alachua, Florida and currently employs 622 full-time employees. The company offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.
최신 재무제표(Form-10K)에 따르면, AxoGen Inc의 총 자산은 $0이며, 순손실입니다.
AXGN의 주요 재무 비율은 무엇인가요?
AxoGen Inc의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
AxoGen Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
AxoGen Inc 주요 수익원은 Peripheral Nerve Regeneration and Repair이며, 최신 수익 발표에서 수익은 187,338,000입니다. 지역별로는 United States이 AxoGen Inc의 주요 시장이며, 수익은 187,338,000입니다.